AstraZeneca (NYSE: AZN) announced that the FDA has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback